Converge Bio
The Generative AI Lab for the Life Sciences
Tel Aviv, Israel · Founded 2024 · $25.0M raised
- Headquarters
- Tel Aviv
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- converge-bio.com
- Total Funding
- $25.0M
- Last Round
- $25.0M Series AJan 2025
- Rounds
- 1
About
Converge Bio is an AI-driven drug discovery company founded in 2024 and headquartered in Tel Aviv, Israel with a presence in Boston, Massachusetts. The company provides a generative AI lab for life sciences, helping pharmaceutical and biotech customers accelerate drug development through AI-powered molecule design, discovery, and manufacturing optimization. Founded by CEO Dov Gertz, CTO Oded Kalev, and CSO Iddo Weiner, Converge Bio raised a $5.5M seed in 2024 and a $25M Series A in January 2026 led by Bessemer Venture Partners. The company has completed over 40 programs with more than a dozen pharma and biotech clients globally.
Summary
Converge Bio is an Artificial Intelligence company based in Tel Aviv, Israel, founded in 2024. It has raised $25.0M in total across 1 round, most recently a $25.0M Series A round in Jan 2025.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2025
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...